Pfizer Inc (PFE.N)
38.97USD
9:07pm IST
$-0.91 (-2.28%)
$39.88
$39.75
$39.78
$38.42
4,540,867
7,885,203
$46.46
$34.38
About
Overall
| Beta: | 0.99 |
| Market Cap(Mil.): | $214,682.30 |
| Shares Outstanding(Mil.): | 5,955.13 |
| Dividend: | 0.32 |
| Yield (%): | 3.55 |
Financials
| PFE.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 26.26 | 29.30 | 32.55 |
| EPS (TTM): | 1.37 | -- | -- |
| ROI: | 6.00 | 14.23 | 13.83 |
| ROE: | 13.80 | 15.46 | 15.25 |
U.S., China key to GSK's consumer venture with Pfizer
LONDON The United States and China will be key focuses for the consumer healthcare venture being formed by GlaxoSmithKline and Pfizer, as the companies look to build on strong existing positions in those markets.
U.S., China key to GSK's consumer venture with Pfizer
LONDON, April 4 The United States and China will be key focuses for the consumer healthcare venture being formed by GlaxoSmithKline and Pfizer, as the companies look to build on strong existing positions in those markets.
Shareholder pushing for mandatory arbitration seeks to block J&J's annual meeting
There has been a significant escalation in the fight over whether corporations can require shareholders to arbitrate claims against the company.
Pfizer buys stake in French gene therapy firm Vivet
Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.
Pfizer buys stake in French gene therapy firm Vivet
Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.
UPDATE 1-Pfizer buys stake in French gene therapy firm Vivet
March 20 Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.
Pfizer buys stake in French gene therapy firm Vivet
March 20 Pfizer Inc said on Wednesday it has acquired a 15 percent stake in Vivet Therapeutics, and has an exclusive option to fully acquire the privately held French company that develops gene therapies for liver disorders.
FDA approves Pfizer's biosimilar to Roche's Herceptin
The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin.
UPDATE 1-FDA approves Pfizer's biosimilar to Roche's Herceptin
March 11 The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin.
FDA approves Pfizer's biosimilar to Roche's Herceptin
March 11 The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster treatment for breast cancer, Herceptin.
Estimates